Alentis Therapeutics, a Basel, Switzerland – based biotech company developing novel therapeutics in advanced liver disease and cancer, closed a CHF 12.5m (€11.1m; USD12.5m) Series A financing.
The round was co-led by BioMedPartners and BB Pureos Bioventures with participation from BPI France, Schroder Adveq and the German High-Tech Gründerfonds.
Markus L.E. Ewert, PhD, MBA has joined the company as Chief Executive Officer. He was previously CBO at Ablynx, contributing to both its US IPO and highly successful sale to Sanofi. Before, Ewert led global corporate development at GE Healthcare, had leadership positions at Novartis, and has a track record of building businesses based on innovations.
Founded on research of the laboratory of Prof. Thomas Baumert, MD at the University of Strasbourg, the Inserm Institute for Viral and Liver Disease, the Laboratory of Excellence HepSYS and the Institut Hospitalo-Universitaire Strasbourg as well as other collaborators, including Prof. Yujin Hoshida, MD at the University of Texas Southwestern in Dallas, Alentis is advancing a humanized monoclonal antibody against a target that plays a key role in the pathology of liver fibrosis and hepatocellular carcinoma (HCC). Its research is powered by its proprietary drug discovery platform, which is based on a prognostic liver disease signature holding promise for the discovery and development of further drug candidates to treat advanced liver diseases and cancer.
The company also has a subsidiary in Strasbourg (France) and a branch in Germany.